eXegenics Inc.

The first few Big Pharma moves into RNA interference were tentative and tightly circumscribed, low risk target- or therapeutic area-specific alliances built around indications where localized delivery

Though apparently dominated by Alnylam and Merck, the RNAi space is enjoying a surge of investment, newcomers, and INDs. Is there freedom to operate or are companies and their backers counting on bein

When UK cell therapy company CellFactors failed to raise money last year, one of its shareholders stepped in as COO, bringing commercial experience and a customer focus to a group that lacked both. Ce